PRIMARY IGA NEPHROPATHY
Clinical trials for PRIMARY IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could slow kidney failure in High-Risk patients
Disease control Recruiting nowThis study tests a new medicine called sefaxersen for people with a kidney disease called IgA nephropathy that is getting worse despite standard care. The drug aims to reduce protein in the urine and slow down kidney damage. About 428 adults will receive either sefaxersen or a pl…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 17, 2026 04:25 UTC
-
New drug YKST02 shows promise for kidney disease in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called YKST02 in 12 adults with IgA nephropathy, a kidney disease. The main goal is to see if the drug is safe and if it can reduce protein in the urine, a sign of kidney damage. Participants receive the drug by IV and are closely monitored…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
Kidney drug iptacopan tested for Long-Term safety in IgA nephropathy patients
Disease control Recruiting nowThis study looks at the long-term safety of a drug called iptacopan in adults with a kidney disease called primary IgA nephropathy. Participants have already completed an earlier study with iptacopan and can continue receiving the drug until it becomes commercially available. The…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:41 UTC